Canopy Growth Corp. of Smiths Falls, Ont., has an agreement to buy pharmaceutical distributor MedCann, which has placed the Canadian marijuana company’s Tweed-branded cannabis strains in German pharmacies.
“Germany has begun a process of enabling medical access to cannabis and through a policy that recognized Canopy as the first legal supply source from North America,” said Canopy chairman and CEO Bruce Linton in a statement.
“This acquisition establishes a distinct and purely medicinal corporate entity that helps us today but also positions us for domestic medicinal production inside Germany if the regulatory environment shifts.”
OBJ360 (Sponsored)
Charity flow-throughs help major donors stretch
Whether it is in Ottawa, or just about any Canadian city, capital campaigns abound. Hospitals, universities and every charity or foundation in between are seeking millions to meet the needs
Giving Guide: The Snowsuit Fund
What we do Now in our 43rd season, The Snowsuit Fund purchases and distributes nearly 17,000 snowsuits annually to children 15 years and younger from low-income families living in Ottawa.
Mr. Linton has previously said that he wants Canopy to “dominate” the global marijuana market.
The German purchase, subject to approvals, will be made with 674,631 Canopy shares (TSX:CGC), which on Monday closed at $11.22 on the Toronto Stock Exchange, up 5.85 per cent.
At that value, the transaction would be worth about $7.57 million upon closing.
Canopy would also pay up to 490,000 shares over two years if certain performance targets are achieved, bringing the total number of shares to be issued to about 1.16 million – one per cent of Canopy’s current common shares.
Canopy Growth currently has a market value of about $1.29 billion, based on Monday’s stock price.
